Shared decision-making seen as an important instrument to obtain better research results and gain support and acceptance from the wider public, according to a new position paper published in the Journal of Neuromuscular Diseases
Ottawa, February 6, 2019 – The old-fashioned paternalistic relationship between doctors and patients has gradually evolved into a more collaborative one in the era of patient-centered medicine. Shared decision-making (SDM), in which doctors and patients jointly decide on treatment or care, has emerged as a gold standard model of healthcare. Yet considerably less attention has been given to obtaining the patient perspective in neuromuscular research on such matters as research objectives, study design, or even consent. A position paper in the Journal of Neuromuscular Diseases describes conclusions reached at an international workshop that focused on finding creative solutions to integrate and enhance the patient’s point of view in neuromuscular research.
“I need to revise my grant application to include patient perspective in my research project!” commented attendee Valeria Sansone, MD, Director of the NEMO Centre, Milan (Italy). Dr. Sansone was one of 45 clinicians, healthcare professionals, researchers, patients, caregivers, and representatives from regulatory agencies and pharmaceutical companies from 15 countries who attended. The gathering was convened by the European Neuromuscular Centre (ENMC), an organization funded by neuromuscular patient organizations, upon its 25th anniversary and was held in Milan, Italy from January 19-20, 2018.
“The ENMC, a group of patient organizations for neuromuscular disorders, convened this workshop to familiarize with the concept of SDM, which is new for most patients and researchers in the neuromuscular field,” noted Ellen Sterrenburg, PhD, Chair of the ENMC Executive Committee.
The workshop recommendations include higher patient involvement in research activities related to neuromuscular diseases: clinical trials, sample biobanks/patient registries, and regulatory processes. Educational, structural and cultural changes need to be implemented by all stakeholders: patients and patient organizations, healthcare professionals and regulatory bodies.
In an introductory talk, Ingeborg Meijer PhD, of the Center for Science and Technology Studies (CWTS) of the University of Leiden and Spierziekten Nederland, Baarn (The Netherlands) set the tone of the Workshop by presenting a graphic conceptualizing the levels of patient involvement in decision processes related to health called the “ladder of participation.”
“There is a need for a change in culture in many medical research disciplines in order to succeed in the empowerment of patients, their families and advocates but this change should be adopted also by researchers, doctors, and all other professionals,” explained Dr. Meijer.
Caption: The ladder of participation. By Dr. Anna Ambrosini, adapted from: de Wit MP, Kvien TK, Gossec L. Patient participation as an integral part of patient-reported outcomes development ensures the representation of the patient voice: a case study from the field of rheumatology. RMD Open. 2015;1(1):e000129.
During the session on biobanks and registries, Hanns Lochműller, Senior Scientist at the CHEO Research Institute, said, “Rare disease research centers offer an ideal setup to implement and integrate patient involvement at all levels.” He pointed to several examples of patient co-creation in research programs such as the UK myotonic dystrophy registry, which is patient driven but professionally supported. In this registry, the patient initiates the registration and names a doctor to enter the patient’s clinical data, eliminating possible biases of past registries. Patients have also played a significant role in the TREAT-NMD global registries and in developing the International Charter of principles for sharing bio-specimens and data. “Patient commitment is facilitated when registries and researchers commit to reporting research results back to the data providers, the patients, and families. A challenge is educating scientists to be flexible and change their research protocols according to the priorities of the research participants,” explained Dr. Lochműller, co-Editor-in-Chief of The Journal of Neuromuscular Diseases.
Patient participation in biobanks would also benefit from SDM. To accomplish this, the ENMC Workshop provided specific educational (e.g., the consent form should be updated to accommodate modern techniques applied to cell lines and biopsies, and written together with patient organizations to ensure understanding”), cultural (e.g., “patients who donate data or samples are to be seen as partners in research and should be aware of this role”) and structural recommendations (e.g., “research information should go back to patients in form of regular newsletters and updates”).
In a session on clinical trials, participants agreed that involvement of persons with a NMD (or patient organizations) in clinical trials, as experts of their own disease, should happen in a proactive way from the beginning and through the discussion on trial design options. As an illustration,. Baziel van Engelen, MD, PhD, professor of neuromuscular diseases at Radboud University Nijmegen Medical Centre and former ENMC Research Director, presented his experience with patient participation in the clinical trial OPTIMISTIC for myotonic dystrophy type 1. A unique feature of the trial design was asking each patient which determinant of health status the individual wanted to change. “The concept of promoting health (vs. decreasing the disease) and treating the patient (vs. treating the disease) led in this case to an impressive retention level throughout the study and to a very high satisfaction of the patients involved,” said Prof. Dr. van Engelen.
Patient input may come from individual patients or patient organizations, such as EURORDIS and those that are condition-specific. Several initiatives are in place to help patients achieve relevant competencies and encourage those who want to take on the responsibilities of being knowlegeable patient representatives. “Having the patient voice in a clinical trial is not only feasible, it should be a logical and natural thing,” commented Dr. Lochműller.
# # #
“The Position of Neuromuscular Patients in Shared Decision Making: Report from the 235th ENMC Workshop: Milan, Italy, January 19-20, 2018,” by Hanns Lochmüller, Anna Ambrosini, Baziel van Engelen, Mats Hansson, Aad Tibben, Alexandra Breukel, Ellen Sterrenburg, Guus Schrijvers, Ingeborg Meijer, George Padberg, Holly Peay, Lucia Monaco, Mike Snape, Anne Lennox, Elena Mazzone, Nathalie Bere, Mencia de Lemus, Erik Landfeldt, and Raffaella Willmann on behalf of the 235th ENMC workshop study group (DOI 10.3233/JND-180368), published in the Journal of Neuromuscular Diseases, Volume 6, Issue 1 (February 2019) by IOS Press. The article is openly available at https://content.iospress.com/articles/journal-of-neuromuscular-diseases/jnd180368.
This Workshop was made possible thanks to the financial support of the European Neuromuscular Centre (ENMC) and ENMC main sponsors: Association Française contre les Myopathies (France), Deutsche Gesellschaft für Muskelkranke (Germany), Muscular Dystrophy UK, Muskelsvindfonden (Denmark), Prinses Beatrix Spierfonds (The Netherlands), Schweizerische Stiftung für die Erforschung der Muskelkrankheiten (Switzerland), Telethon Foundation (Italy), Spierziekten Nederland (The Netherlands) and the Finnish Neuromuscular Association (Finland). Audentes Therapeutics supported travel costs from non-ENMC member countries.
ABOUT THE CHEO RESEARCH INSTITUTE
The CHEO Research Institute coordinates the research activities of CHEO and is affiliated with the University of Ottawa. Its three programs of research are molecular biomedicine, health information technology, and evidence to practice research. Key themes include cancer, diabetes, obesity, mental health, emergency medicine, musculoskeletal health, electronic health information and privacy, and genetics of rare disease. The CHEO Research Institute makes discoveries today for healthier kids tomorrow. For more information, visit www.cheori.org
ABOUT THE JOURNAL OF NEUROMUSCULAR DISEASES (JND)
The Journal of Neuromuscular Diseases facilitates progress in understanding the molecular genetics/correlates, pathogenesis, pharmacology, diagnosis and treatment of acquired and genetic neuromuscular diseases (including muscular dystrophy, myasthenia gravis, spinal muscular atrophy, neuropathies, myopathies, myotonias, and myositis). The journal publishes research reports, reviews, and short communications. Guided by Editors-in-Chief Carsten G. Bönnemann (National Institute of Neurological Disorders and Stroke, NIH) and Hanns Lochmüller (Children’s Hospital of Eastern Ontario Research Institute, Ottawa, Canada), the journal is dedicated to providing an open forum for original research in basic science, translational, and clinical research that will improve our fundamental understanding and lead to effective treatments of neuromuscular diseases. www.iospress.nl/journal/journal-of-neuromuscular-diseases
ABOUT IOS PRESS
IOS Press is headquartered in Amsterdam with satellite offices in the USA, Germany, India and China and serves the information needs of scientific and medical communities worldwide. IOS Press now publishes over 100 international journals and about 75 book titles each year on subjects ranging from computer sciences and mathematics to medicine and the natural sciences. www.iospress.com